Oral bisphosphonate-related osteonecrosis of the jaw: Incidence, clinical features, prevention, and treatment recommendations

Noam Yarom*, Towy Sorel Lazarovici, Sharon Elad

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Biphosphonate-related osteonecrosis of the jaw (BRONJ) is a devastating side effect of oral bisphosphonates associated with patient morbidity and high financial burden to health services. BRONJ is usually associated with parenteral use of bisphosphonates in oncologic patients, but its incidence among individuals with osteoporosis who take oral bisphosphonates is on the rise. In the absence of definitive treatment for BRONJ, every effort should be made toward its prevention. The patients must be informed about the extremely small but proven risk of oral BRONJ and be recommended to undergo periodic dental evaluation and meticulous oral hygiene. Once BRONJ occurs, long-term antibiotic therapy and superficial curettage may be beneficial.

Original languageEnglish
Pages (from-to)27-31
Number of pages5
JournalClinical Reviews in Bone and Mineral Metabolism
Volume8
Issue number1
DOIs
StatePublished - Mar 2010

Keywords

  • Alendronate
  • Bisphosphonates
  • Jaws
  • Osteonecrosis
  • Osteoporosis

Fingerprint

Dive into the research topics of 'Oral bisphosphonate-related osteonecrosis of the jaw: Incidence, clinical features, prevention, and treatment recommendations'. Together they form a unique fingerprint.

Cite this